Revenue

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

Hapag-Lloyd renews a key $550M funding facility, revealing a critical strategy for financial resilience in the turbulent global shipping industry.

A massive silver discovery in Nevada isn't just a win for one company; it's a strategic move to secure America's tech and energy future. Here's why.

A $104M loan for a Lynbrook luxury tower reveals a major shift in real estate finance and highlights soaring demand for transit-oriented living.

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

A startup claims to solve AI's 95% pilot failure rate with a self-improving engine. We analyze if this is the key to unlocking true enterprise AI.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Law firm Gunderson Dettmer's major partner expansion signals confidence not in the whole market, but in the AI-driven, high-value core of the venture economy.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A home remodeler is a top IT workplace. The defense sector must learn from its model for talent development, which holds strategic national security lessons.

A new patent for reactivated carbon technology offers a circular solution to destroy "forever chemicals," promising a reliable path for U.S. water safety.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

The waterpark giant is investing millions to trade slides for serenity. We analyze Kalahari's strategic leap into the booming luxury experience market.

A new partnership aims to fix the broken music industry with a global commerce engine and advanced AI, giving artists true ownership of their careers.

Evvy's new at-home UTI test promises fast, precise results. But can its high-tech, high-cost model truly revolutionize women's healthcare?

Why a top security leader's move from a tech giant to a specialized firm signals a major shift in the fight for digital resilience. A deep dive.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.